Edwin M Posadas
Overview
Explore the profile of Edwin M Posadas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
2510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang L, Teng P, Cavassani K, Wang J, Grasso C, Watson J, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40063516
Background: Circulating tumor cells (CTCs) with a very-small-nuclear phenotype (vsnCTCs) in prostate cancer (PCa) are characterized by nuclei smaller than 8.5 μm. Our previous studies established an association between vsnCTCs...
2.
Yang Y, Kim J, Wang Z, Kim J, Kim S, Cho G, et al.
J Clin Invest
. 2025 Feb;
PMID: 39946200
Steatotic liver enhances liver metastasis of colorectal cancer, but this process is not fully understood. Steatotic liver induced by a high-fat diet (HFD) increases cancer-associated fibroblast (CAF) infiltration and collagen...
3.
Ju Y, Watson J, Wang J, Yen Y, Gevorkian L, Chen Z, et al.
Drug Resist Updat
. 2025 Feb;
79:101207.
PMID: 39914189
Background: B7-H3 is a promising target for cancer therapy, notably in prostate cancer (PCa), particularly in metastatic, castration-resistant PCa (mCRPC). With the development of B7-H3-targeted therapies, there is a need...
4.
Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, et al.
Nucleic Acids Res
. 2024 Jun;
52(13):7740-7760.
PMID: 38932701
Androgen receptor- (AR-) indifference is a mechanism of resistance to hormonal therapy in prostate cancer (PC). Here we demonstrate that ONECUT2 (OC2) activates resistance through multiple drivers associated with adenocarcinoma,...
5.
Madan R, Posadas E, Lee R
Nat Rev Urol
. 2024 Jun;
21(11):646-648.
PMID: 38886519
No abstract available.
6.
Friedrich N, Luu M, Gale R, Chaplin A, Ballas L, Sandler H, et al.
Urol Oncol
. 2024 May;
42(9):288.e7-288.e15.
PMID: 38762384
Introduction: Multidisciplinary consultations improve decisional conflict and guideline-concordant treatment for men with prostate cancer (PC), but differences in the content discussed by specialty during consultations are unknown. Methods: We audiorecorded...
7.
Perri G, Vilas Boas V, Nogueira M, Mello Junior E, Coelho A, Posadas E, et al.
Cancer Immunol Immunother
. 2024 Apr;
73(6):110.
PMID: 38662248
Interleukin (IL)-33 is an important cytokine in the tumour microenvironment; it is known to promote the growth and metastasis of solid cancers, such as gastric, colorectal, ovarian and breast cancer....
8.
Solanki A, Kamrava M, Posadas E, Freedland S, Ballas L, Sandler H, et al.
Cancer
. 2024 Mar;
130(11):1916-1929.
PMID: 38529566
Prostate cancer is the most common malignancy among men worldwide, and androgen-deprivation therapy (ADT) is a mainstay of treatment. There are observational data demonstrating an increased risk of cardiovascular events...
9.
Madan R, Yu E, Posadas E, Lee R, Karzai F, Choyke P
J Clin Oncol
. 2024 Mar;
42(19):2242-2244.
PMID: 38489582
#PSMA is amazing new tech but is using it to expedite the call of disease progression helping #ProstateCancer patients?
10.
Morgan T, Boorjian S, Buyyounouski M, Chapin B, Chen D, Cheng H, et al.
J Urol
. 2024 Feb;
211(4):509-517.
PMID: 38421253
Purpose: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a...